15.21

4.28% -0.69

Intellia Therapeutics Inc (NTLA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$15.90

Aprire:

$15.815

Volume 24 ore:

3.21M

Relative Volume:

0.47

Capitalizzazione di mercato:

$1.76B

Reddito:

$52.86M

Utile/perdita netta:

$-480.19M

Rapporto P/E:

-3.2431

EPS:

-4.6899

Flusso di cassa netto:

$-421.82M

1 W Prestazione:

+21.76%

1M Prestazione:

+61.57%

6M Prestazione:

+6.88%

1 anno Prestazione:

+34.81%

Intervallo 1D:

$15.08

$15.95

Intervallo di 1 settimana:

$11.93

$15.95

Portata 52W:

$5.90

$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Nome

Intellia Therapeutics Inc

Settore

Healthcare (1119)

Industria

Biotechnology (625)

Telefono

857-285-6200

Indirizzo

40 ERIE STREET, CAMBRIDGE, MA

Dipendente

598

Cinguettio

@intelliatweets

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

NTLA's Discussions on Twitter

Confronta NTLA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NTLA Intellia Therapeutics Inc	15.20	1.84B	52.86M	-480.19M	-421.82M	-4.6899
VRTX Vertex Pharmaceuticals Inc	462.89	118.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	748.65	79.40B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	813.59	51.18B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	360.52	48.88B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	339.19	37.49B	4.98B	69.59M	525.67M	0.5197

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-12	Downgrade	Wolfe Research	Outperform → Peer Perform
2025-11-11	Downgrade	Evercore ISI	Outperform → In-line
2025-11-07	Downgrade	JP Morgan	Neutral → Underweight
2025-10-28	Downgrade	Bernstein	Outperform → Mkt Perform
2025-10-28	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-10-27	Downgrade	Guggenheim	Buy → Neutral
2025-10-27	Downgrade	William Blair	Outperform → Mkt Perform
2025-10-06	Aggiornamento	Citizens JMP	Mkt Perform → Mkt Outperform
2025-04-21	Aggiornamento	Wolfe Research	Peer Perform → Outperform
2025-03-05	Iniziato	H.C. Wainwright	Buy
2025-02-28	Downgrade	Goldman	Neutral → Sell
2025-02-28	Downgrade	JP Morgan	Overweight → Neutral
2025-01-27	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2024-02-23	Downgrade	Goldman	Buy → Neutral
2024-02-15	Iniziato	Wolfe Research	Peer Perform
2023-04-13	Iniziato	Canaccord Genuity	Buy
2023-03-21	Iniziato	Bernstein	Outperform
2023-03-14	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-02-01	Iniziato	Cantor Fitzgerald	Overweight
2023-01-24	Aggiornamento	Citigroup	Sell → Neutral
2023-01-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2022-10-11	Iniziato	Morgan Stanley	Overweight
2022-09-21	Iniziato	JP Morgan	Overweight
2022-09-01	Iniziato	Citigroup	Sell
2022-06-17	Iniziato	BMO Capital Markets	Market Perform
2022-06-16	Iniziato	BofA Securities	Buy
2022-04-28	Iniziato	Credit Suisse	Outperform
2022-02-18	Iniziato	William Blair	Outperform
2022-02-07	Aggiornamento	Oppenheimer	Perform → Outperform
2022-01-31	Iniziato	Cowen	Outperform
2022-01-07	Iniziato	Piper Sandler	Overweight
2021-10-05	Iniziato	Guggenheim	Buy
2021-09-24	Iniziato	Stifel	Buy
2021-06-28	Reiterato	H.C. Wainwright	Buy
2021-06-11	Iniziato	H.C. Wainwright	Buy
2021-05-07	Aggiornamento	ROTH Capital	Neutral → Buy
2021-05-04	Iniziato	RBC Capital Mkts	Outperform
2021-03-04	Iniziato	JMP Securities	Mkt Outperform
2020-12-22	Downgrade	Robert W. Baird	Outperform → Neutral
2020-10-27	Iniziato	Truist	Buy
2020-10-14	Iniziato	Wells Fargo	Overweight
2020-09-18	Iniziato	Goldman	Buy
2020-02-28	Aggiornamento	Oppenheimer	Perform → Outperform
2020-02-14	Downgrade	Wedbush	Outperform → Neutral
2019-11-01	Aggiornamento	Raymond James	Mkt Perform → Outperform
2019-07-09	Iniziato	Robert W. Baird	Outperform
2019-06-10	Iniziato	ROTH Capital	Neutral
2019-05-03	Aggiornamento	Wedbush	Neutral → Outperform
2019-04-12	Iniziato	Evercore ISI	Outperform
2018-11-02	Downgrade	Wedbush	Outperform → Neutral
2018-10-29	Iniziato	Credit Suisse	Neutral
2018-09-21	Iniziato	Raymond James	Mkt Perform
2018-05-15	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2018-03-08	Iniziato	JMP Securities	Mkt Outperform
2017-11-01	Reiterato	Jefferies	Buy
2017-06-22	Ripresa	Jefferies	Buy
2017-03-28	Iniziato	Chardan Capital Markets	Buy
2016-08-05	Aggiornamento	Jefferies	Hold → Buy

Mostra tutto

Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie

Jan 22, 2026

Risk Check: Can Intellia Therapeutics Inc. grow without dilutionJuly 2025 Trade Ideas & Scalable Portfolio Growth Ideas - mfd.ru

Jan 22, 2026

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.

Jan 22, 2026

Jan 21, 2026

Earnings Miss: Will Intellia Therapeutics Inc benefit from government policyJuly 2025 Market Mood & Accurate Buy Signal Alerts - baoquankhu1.vn

Jan 21, 2026

Intellia Therapeutics (NASDAQ:NTLA) Shares Up 7.9%Time to Buy? - MarketBeat

Jan 21, 2026

Portfolio Update: Does Intellia Therapeutics Inc offer margin of safetyMarket Trend Review & Verified Stock Trade Ideas - baoquankhu1.vn

Jan 21, 2026

Is Intellia Therapeutics (NTLA) Pricing Make Sense After Sharp Rebound And DCF Upside Signals - simplywall.st

Jan 21, 2026

Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate - Seeking Alpha

Jan 21, 2026

Jan 20, 2026

ARK Investment buys 560K shares of Intellia Therapeutics - MSN

Jan 20, 2026

Intellia Therapeutics (NTLA) Is Up 6.5% After ARK’s Stock Buying And JPM Pipeline Update – Has The Bull Case Changed? - Yahoo Finance

Jan 20, 2026

Is Intellia Therapeutics (NTLA) Pricing Make Sense After Recent 35% Monthly Surge - Yahoo Finance

Jan 20, 2026

Jan 19, 2026

Assessing Intellia Therapeutics (NTLA) Valuation After Recent Share Price Rebound and Conflicting Fair Value Signals - Yahoo Finance

Jan 19, 2026

Treasury Yields: What dividend growth rate does Intellia Therapeutics Inc offerWeekly Trade Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn

Jan 19, 2026

Jan 18, 2026

Intellia Therapeutics (NASDAQ:NTLA) Downgraded to Sell Rating by Wall Street Zen - MarketBeat

Jan 18, 2026

Jan 16, 2026

Intellia Therapeutics (NTLA) Stock: Cathie Wood Continues Three-Day Buying Streak - MEXC

Jan 16, 2026

Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD - Stocktwits

Jan 16, 2026

Intellia Therapeutics (NTLA) Stock: Cathie Wood’s ARK Buys Third Day Running - Blockonomi

Jan 16, 2026

Sumitomo Mitsui Trust Group Inc. Sells 316,409 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat

Jan 16, 2026

Cathie Wood’s ARK made just one buy last session — and it’s a biotech stock up nearly 30% YTD - MSN

Jan 16, 2026

A Look At Intellia Therapeutics (NTLA) Valuation After ARK’s Added Stake And J.P. Morgan Conference Spotlight - Sahm

Jan 16, 2026

Cathie Wood’s ARK adds to Intellia stock holdings on January 15 By Investing.com - Investing.com South Africa

Jan 16, 2026

Jan 15, 2026

ARK Investment Increases Stake in Intellia Therapeutics (NTLA) - GuruFocus

Jan 15, 2026

Cathie Wood’s ARK adds to Intellia stock holdings on January 15 - Investing.com India

Jan 15, 2026

ARK Invest Acquires 56,769 Shares of Intellia, Stock Rises 2% - Intellectia AI

Jan 15, 2026

JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death - Yahoo Finance

Jan 15, 2026

Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety EventHas The Bull Case Changed? - Sahm

Jan 15, 2026

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clinical Hold On Lead Gene Editing Trial - Sahm

Jan 15, 2026

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat

Jan 15, 2026

Intellia Therapeutics (NASDAQ:NTLA) Best Nasdaq Stocks Clinical Innovation - Kalkine Media

Jan 15, 2026

Jan 14, 2026